Outlook Refiles Ophthalmic Bevacizumab In US

Follows Withdrawal Of Earlier BLA After FDA Asked For Additional Information

 
• By Dave Wallace

Outlook Therapeutics has confirmed the re-submission of its proposed ophthalmic bevacizumab with the US Food and Drug Administration, after the agency requested further information.

Eye fibre optic rainbow
Outlook has refiled its ophthalmic bevacizumab application with the FDA • Source: Shutterstock

Outlook Therapeutics has confirmed the re-submission of its ONS-5010 proposed bevacizumab product to treat wet age-related macular degeneration with the US Food and Drug Administration. The firm anticipates “potential FDA marketing approval in 2023.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products